Gilead Sciences, INC.

Concentrated strategyQuality / disciplined sizing

Total reported value

$2.1B

Reporting period: 2026-03-31 · Number of holdings: 6

GILEAD SCIENCES, INC. disclosed 6 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $2.1B and a quarterly turnover rate of 23.9%.

Browse other institutions with $1B to $10B AUM Browse other institutions starting with "G"

Personality snowflake

Concentration: 100
Portfolio Stability: 23.92
Momentum/Contrarian: 50
Sector conviction: 0
Diversification: 12
Sizing Uniformity: 90.38

Recent moves

Add ACLXGBX
0.0%　$333.5M
Trim RCUS
0.0%　-$70.1M
Trim LKFT
0.0%　-$49.4M
Trim ASMB
0.0%　-$28.2M
Trim KYTX
0.0%　-$3.2M
Trim 98422T100
-92.9%　-$359.5K

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#	Ticker	Issuer	Asset Subclass	Weight	Weight Change	Shares Change
1	ACLXGBX	Arcellx INC	Stock-Other	36.44%	+13.80%	—
2	RCUS	Arcus Biosciences INC	Stock-Other	32.05%	-6.64%	—
3	LKFT	Lakefront Biotherapeutic-adr	Stock-Other	23.67%	-4.78%	—
4	ASMB	Assembly Biosciences INC	Stock-Other	5.90%	-2.02%	—
5	KYTX	Kyverna Therapeutics INC	Stock-Other	1.68%	-0.32%	—
6	✓	Xilio Therapeutics INC	Stock-Other	0.26%	-0.04%	-92.86%

Reported value over time

Sector allocation

Not enough sector-mapped data yet

Sector allocation over time

Quarterly history

Period	Holdings	Total value	Stability	Top holdings
2026-03-31	6	$2.1B	24	1ACLXGBX 2RCUS 3LKFT Top holdings2026-03-31 1.ACLXGBX 2.RCUS 3.LKFT 4.ASMB 5.KYTX 6.98422T
2025-12-31	6	$1.9B	32	1RCUS 2LKFT 3ACLXGBX Top holdings2025-12-31 1.RCUS 2.LKFT 3.ACLXGBX 4.ASMB 5.KYTX 6.98422T
2025-09-30	9	$1.8B	41	1LKFT 2ACLXGBX 3RCUS Top holdings2025-09-30 1.LKFT 2.ACLXGBX 3.RCUS 4.ASMB 5.N5749R 6.TNGX 7.KYTX 8.98422T 9.CYPH
2025-06-30	14	$1.3B	0	1LKFT 2ACLXGBX 3RCUS Top holdings2025-06-30 1.LKFT 2.ACLXGBX 3.RCUS 4.ASMB 5.TNGX 6.N5749R 7.KYTX 8.98422T 9.43906K 10.CYPH
2025-03-31	14	$1.2B	0	1ACLXGBX 2LKFT 3RCUS Top holdings2025-03-31 1.ACLXGBX 2.LKFT 3.RCUS 4.ASMB 5.N5749R 6.KYTX 7.TNGX 8.98422T 9.KLRS 10.43906K
2024-12-31	16	$1.6B	0	1ACLXGBX 2LKFT 3RCUS Top holdings2024-12-31 1.ACLXGBX 2.LKFT 3.RCUS 4.ASMB 5.N5749R 6.KYTX 7.CYPH 8.TNGX 9.98422T 10.019818

Holding changes this quarter

Gilead Sciences, INC.'s most significant position changes for 2026-03-31: Trim: Xilio Therapeutics INC — shares -92.86%.

Position changes disclosed by Gilead Sciences, INC. for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#	Ticker	Issuer	Weight Change	Shares Change	Action
1	ACLXGBX	Arcellx INC	+13.8%	—	Unchanged
2	✓	Xilio Therapeutics INC	0%	-92.86%	Trim
3	KYTX	Kyverna Therapeutics INC	-0.3%	—	Unchanged
4	ASMB	Assembly Biosciences INC	-2%	—	Unchanged
5	LKFT	Lakefront Biotherapeutic-adr	-4.8%	—	Unchanged
6	RCUS	Arcus Biosciences INC	-6.6%	—	Unchanged

FAQ

What is Gilead Sciences, INC. and what type of investor is it?

Gilead Sciences, INC. is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $2.1B, spread across 6 disclosed positions.

What are Gilead Sciences, INC.'s largest equity positions?

Based on the latest 13F filing, Gilead Sciences, INC.'s top holdings by market value are: 1. Arcellx INC (ACLXGBX) — $771.7M (36.4%) 2. Arcus Biosciences INC (RCUS) — $678.8M (32.0%) 3. Lakefront Biotherapeutic-adr (LKFT) — $501.2M (23.7%) 4. Assembly Biosciences INC (ASMB) — $125.0M (5.9%) 5. Kyverna Therapeutics INC (KYTX) — $35.6M (1.7%)

What changes did Gilead Sciences, INC. make in its most recent portfolio filing?

In the latest quarter, Gilead Sciences, INC. took a more defensive posture — trimming 1 positions and completely exiting 0 holdings. The largest of these moves: Trim: Xilio Therapeutics INC — shares -92.86%

What sectors does Gilead Sciences, INC. focus on?

Sector breakdown data is not yet available for Gilead Sciences, INC.. Check back after the next 13F processing cycle.